Synthekine Announces AACR 2026 Oral Presentation of Updated Phase 1a/1b Clinical and Translational Data for STK‑012 in First‑Line Nonsquamous NSCLC with Features of ...

Synthekine Inc., an engineered cytokine therapeutics company, today announced that updated clinical and translational data from a Phase 1a/1b clinical trial of its α/β biased IL-2 partial agonist, STK ...
BioWorld

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful for the treatment of psychiatric ...
Medscape

Positive Phase 3 Results for First-in-Class Parkinson's Med

PHILADELPHIA — Tavapadon, an experimental first-in-class oral selective partial D1/D5 dopamine receptor agonist for Parkinson's disease (PD), was shown to significantly reduce disease burden in two ...
BioWorld

SARs to convert full cannabinoid receptor agonists to partial ones

Activation of cannabinoid receptors in the peripheral nervous system may help treat inflammatory and gastrointestinal disorders as well as pain, and several full agonists have been reported but they ...
EurekAlert!

Structural findings reveal how distinct GPCR ligands create different levels of activation

Corresponding author Georgios Skiniotis, PhD, St. Jude Center of Excellence for Structural Cell Biology director and Department of Structural Biology member. (MEMPHIS, Tenn. – December 22, 2025) ...